{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT01746654: Phase 1/Phase 2 Interventional Completed Infectious Disease
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pemziviptadil [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:mipeginterferon alfa-2b [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03659136: Phase 2 Interventional Completed Breast Neoplasms
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02204813: Phase 1 Interventional Completed Bypass, Gastric
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:rovalpituzumab [INN]
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT03578029: Phase 2 Interventional Terminated Junctional Epidermolysis Bullosa
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:efpegsomatropin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01439971: Phase 1 Interventional Completed Hemophilia A
(2011)
Source URL:
Class:
PROTEIN
